What's New

Agreement on major articles of contract for collaboration for CT-P10, in Japan

2017/04/26

Tokyo, Japan, April 26, 2017, Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereinafter referred to as “Nippon Kayaku”) and Celltrion Healthcare Co., Ltd. (Head Office: Incheon, South Korea; CEO: Manhoon.Kim) announced that both companies have reached an agreement on major articles of contract for collaboration for a biosimilar “rituximab (genetical recombinant) preparation” (development code: CT-P10) of which global phase III study which includes Japan is being conducted by Celltrion, Inc. (Head Office: Incheon, South Korea; Co-representative: WooSung.Kee and HyoungKi.Kim).

CT-P10 is a biosimilar preparation of rituximab, a monoclonal antibody that plays an important role in the treatment of diseases including malignant lymphoma. Celltrion received approval for manufacturing and marketing of CT-P10 preparation in November 2016 for Korea and in February 2017 for Europe.

CT-P10 is the fourth biosimilar for Nippon Kayaku following Fillgrastim BS Inj “NK”, Infliximab BS for I.V. Infusion 100mg “NK” and CT-P6 currently under development. With a goal of early launch of these products, we expect to make a significant contribution to cancer patients, their families and medical professionals.

[Reference material - Profile of Celltrion, Inc.]
Company nameCelltrion, Inc.
LocationIncheon, South Korea
Listed onKOSDAQ
Business areas This company was established in 2002 in a special economic zone in Incheon, South Korea. It has expanded its business and is now one of the leading bio-pharmaceutical companies in Korea. It has developed advanced bio-pharmaceutical production technologies, and quickly began operating its own commercial plant. Its product pipeline includes RemsimaTM, the world’s first approved biosimilar monoclonal antibody, several other biosimilars and new molecular entities.
Celltrion Healthcare Co., Ltd. is the company which possesses exclusive global distribution and marketing rights to all Celltrion, Inc. products.
Linkhttp://www.celltrion.com/


[Inquiries regarding this release:]
Telephone: +81-3-6731-5237
Public Relations & Investor Relations Division
Nippon Kayaku Co., Ltd.
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR